Rate My Professor Alison Haywood

Dr. Alison Haywood serves as Senior Lecturer in the School of Pharmacy and Medical Sciences at Griffith University, within Griffith Health. She holds a Bachelor of Pharmacy (BPharm) and a PhD. Her academic career includes long-term affiliation with the School of Pharmacy at Griffith University's Gold Coast campus, where she has been recognized as Senior Lecturer in publications dating back to 2005. Haywood's research interests center on personalised medicine, with a focus on pharmaceutical stability, excipient compatibility, extemporaneous compounding of oral liquids from commercial tablets, stability of repackaged medications in dose administration aids, and pharmacokinetic considerations in palliative care. Notable studies address degradation issues in compounded isoniazid mixtures due to lactose incompatibility, stability of paracetamol, frusemide, sodium valproate, and clozapine tablets when repackaged, fentanyl transdermal patch adhesion and exposure, and salivary versus plasma pharmacokinetics.

Haywood has contributed significantly to the field through over 100 research outputs, accumulating more than 1,400 citations. Key publications include 'Pharmaceutical excipients – where do we begin?' (2011, 191 citations), 'Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products' (2006, 199 citations), 'Liquid Dosage Forms Extemporaneously Prepared from Commercially Available Products – Considering New Evidence on Stability' (2013, 93 citations), 'Corticosteroids for the management of cancer-related pain in adults' (2015, 132 citations), 'Oral medicinal cannabinoids to relieve symptom burden in the potentially best case scenario' (2020), and recent works such as 'The effects of OPRM1 118A>G on methadone response in advanced cancer patients' (2024) and 'Association of KCNJ6 rs2070995 and methadone response for pain management' (2022). She supervises PhD candidates on projects including biochemical imbalances and micronutrient intervention in aggressive male youth and dream recall as a schizophrenia biomarker. Haywood teaches courses like Specialised Delivery Systems II (4012PHM). In 2021, she joined the APF25 Formulary Working Group. Her collaborations extend to Mater Research Institute – University of Queensland and Menzies Health Institute Queensland.